Neoadjuvant treatment of unresectable liver metastases from colorectal cancer.
There has been increasing interest in the use of neoadjuvant treatment for downstaging and downsizing disease in patients with initially unresectable liver metastases from colorectal cancer with a view to potentially curative surgery. This has been increasingly feasible with the more active treatment combinations presently available based on oxaliplatin or irinotecan. This article reviews the evidence supporting the use of this treatment strategy and discusses the implications of advances in treatment in other metastatic disease settings for these patients and the issues of patient selection and prognostic factors.
Chua
Yu Jo
YJ
Department of Medicine, Royal Marsden Hospital, Surrey and London, United Kingdom. yujo.chua@rmh.nhs.uk
Cunningham
David
D
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary / Q000601:surgery; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000473:pathology*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary / Q000601:surgery; D020360:Neoadjuvant Therapy; D018579:Patient Selection; D011379:Prognosis; D016019:Survival Analysis